Key Points
- I-Mab SVP Cong Claire Xu sold 3,494 shares on June 1 at an average price of $3.94, totaling about $13,766.36. After the sale, Xu still held 290,154 shares, and the trade reduced the position by 1.19%.
- I-Mab’s stock was trading at $1.71 when the article was published, with a market cap of $197.76 million and a 12-month range of $1.28 to $6.79. The company also has a negative price-to-earnings ratio of -4.75.
- Analysts remain mixed on I-Mab, with a consensus rating of Hold and an average price target of $9.00. HC Wainwright reiterated a Buy rating, while other firms issued lower ratings.
I-Mab (NASDAQ:NBP - Get Free Report) SVP Cong Claire Xu sold 3,494 shares of I-Mab stock in a transaction on Monday, June 1st. The stock was sold at an average price of $3.94, for a total value of $13,766.36. Following the completion of the sale, the senior vice president directly owned 290,154 shares of the company's stock, valued at approximately $1,143,206.76. The trade was a 1.19% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.
I-Mab Stock Performance
I-Mab stock opened at $1.71 on Wednesday. The company has a market cap of $197.76 million, a price-to-earnings ratio of -4.75 and a beta of 1.47. The business has a fifty day simple moving average of $2.27. I-Mab has a 12 month low of $1.28 and a 12 month high of $6.79.
I-Mab (NASDAQ:NBP - Get Free Report) last posted its earnings results on Wednesday, April 8th. The company reported ($0.30) EPS for the quarter. On average, research analysts expect that I-Mab will post -0.56 earnings per share for the current fiscal year.
Institutional Trading of I-Mab
A hedge fund recently bought a new stake in I-Mab stock. Brooklyn Investment Group acquired a new position in I-Mab (NASDAQ:NBP - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 12,715 shares of the company's stock, valued at approximately $51,000. Institutional investors and hedge funds own 38.38% of the company's stock.
Analyst Upgrades and Downgrades
NBP has been the subject of several research analyst reports. Wall Street Zen lowered I-Mab from a "hold" rating to a "sell" rating in a report on Saturday, April 11th. Weiss Ratings raised I-Mab from a "sell (e+)" rating to a "sell (d-)" rating in a report on Monday. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $9.00 price objective on shares of I-Mab in a report on Wednesday, April 8th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, I-Mab presently has a consensus rating of "Hold" and an average price target of $9.00.
Read Our Latest Analysis on NBP
About I-Mab
(
Get Free Report)
I-Mab is a clinical-stage biotechnology company focused on the discovery, development and commercialization of biologic therapies for oncology and immunology indications. The company concentrates on advancing antibody-based therapeutics and other protein biologics intended to modulate the immune system to treat cancer and autoimmune or inflammatory diseases. Its development activities span preclinical research through late-stage clinical trials, with an emphasis on creating targeted, differentiated molecules designed to address unmet medical needs.
Headquartered in China with global development activities, I-Mab operates research and development facilities and engages with clinical investigators and regulatory authorities across multiple geographies to support global clinical programs.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
